Index RUT
P/E -
EPS (ttm) -0.65
Insider Own 55.90%
Shs Outstand 82.83M
Perf Week -14.74%
Market Cap 671.90M
Forward P/E -
EPS next Y -0.42
Insider Trans 0.06%
Shs Float 36.58M
Perf Month -15.98%
Income -54.02M
PEG -
EPS next Q -0.17
Inst Own 36.32%
Short Float 10.65%
Perf Quarter -43.24%
Sales 225.44M
P/S 2.98
EPS this Y -1.48%
Inst Trans 4.02%
Short Ratio 6.72
Perf Half Y -14.29%
Book/sh 1.98
P/B 4.08
EPS next Y 28.16%
ROA -16.67%
Short Interest 3.90M
Perf Year -54.92%
Cash/sh 0.70
P/C 11.54
EPS next 5Y 29.80%
ROE -29.23%
52W Range 7.61 - 19.00
Perf YTD -34.84%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -19.69%
52W High -57.37%
Beta 1.05
Dividend TTM -
Quick Ratio 1.78
Sales past 5Y 19.90%
Gross Margin 71.81%
52W Low 6.44%
ATR (14) 0.68
Dividend Ex-Date -
Current Ratio 3.57
EPS Y/Y TTM 24.28%
Oper. Margin -18.84%
RSI (14) 37.15
Volatility 9.04% 6.19%
Employees 574
Debt/Eq 0.67
Sales Y/Y TTM 17.38%
Profit Margin -23.96%
Recom 1.00
Target Price 16.00
Option/Short Yes / Yes
LT Debt/Eq 0.67
EPS Q/Q -63.90%
Payout -
Rel Volume 1.11
Prev Close 7.94
Sales Surprise 2.40%
EPS Surprise -47.61%
Sales Q/Q 17.38%
Earnings May 08 AMC
Avg Volume 579.94K
Price 8.10
SMA20 -13.68%
SMA50 -18.89%
SMA200 -30.40%
Trades
Volume 645,991
Change 2.02%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-29-23 Initiated
William Blair
Outperform
Apr-11-23 Initiated
Stephens
Overweight
$23
Dec-14-22 Resumed
B. Riley Securities
Buy
$32
May-13-24 10:30AM
May-10-24 02:36PM
May-09-24 10:16AM
07:46AM
(Thomson Reuters StreetEvents)
May-08-24 10:55PM
04:05PM
Loading…
04:05PM
May-02-24 04:05PM
Apr-04-24 11:43AM
08:01AM
Apr-01-24 10:32AM
Mar-28-24 04:05PM
04:58AM
Mar-02-24 08:54AM
Mar-01-24 06:44AM
(Thomson Reuters StreetEvents) -5.77%
Feb-29-24 04:35PM
04:05PM
Loading…
04:05PM
Feb-12-24 11:36AM
Feb-06-24 04:05PM
Feb-01-24 08:00AM
Jan-30-24 04:43PM
Jan-26-24 08:00AM
Jan-17-24 08:00AM
Jan-08-24 09:00AM
Jan-05-24 08:00AM
Dec-19-23 04:05PM
Nov-20-23 10:34AM
Nov-16-23 11:31AM
Nov-14-23 04:05PM
08:00AM
Nov-13-23 04:05PM
08:55AM
Loading…
Nov-12-23 08:55AM
Nov-08-23 08:45AM
(Thomson Reuters StreetEvents) -7.15%
Nov-07-23 04:05PM
04:05PM
Nov-06-23 06:42AM
Nov-03-23 08:00AM
Oct-17-23 04:05PM
Sep-11-23 07:00AM
Aug-28-23 04:05PM
Aug-02-23 05:25PM
04:05PM
Jul-28-23 08:00AM
Jul-27-23 08:35AM
Jul-12-23 04:05PM
Jun-12-23 06:34AM
May-23-23 08:00AM
May-05-23 08:42AM
(Thomson Reuters StreetEvents)
May-04-23 06:55PM
04:05PM
Apr-26-23 04:05PM
Apr-24-23 04:05PM
Apr-20-23 04:05PM
Apr-18-23 05:35PM
Apr-11-23 11:49AM
Mar-03-23 08:12AM
(Thomson Reuters StreetEvents)
Mar-02-23 05:35PM
04:05PM
Mar-01-23 04:05PM
Feb-28-23 05:45PM
Feb-23-23 10:00AM
Feb-17-23 02:00PM
Feb-16-23 04:05PM
Feb-12-23 07:14AM
Jan-25-23 10:47PM
04:20PM
Jan-10-23 06:00AM
Dec-29-22 09:36AM
Dec-23-22 05:59AM
Nov-16-22 04:05PM
Nov-15-22 09:55AM
09:40AM
Nov-12-22 07:58AM
Nov-10-22 05:35PM
04:02PM
Nov-09-22 05:55PM
Nov-07-22 06:05PM
Nov-02-22 11:00AM
Oct-27-22 04:02PM
Aug-25-22 04:02PM
Aug-05-22 07:58AM
Aug-04-22 08:00AM
Aug-03-22 04:02PM
Jul-18-22 08:00AM
08:00AM
Jul-13-22 08:00AM
Jun-24-22 07:29AM
Jun-09-22 08:00AM
May-19-22 08:00AM
May-17-22 08:00AM
May-09-22 04:02PM
Apr-27-22 08:00AM
Apr-21-22 09:40AM
Apr-19-22 08:00AM
Apr-18-22 04:03PM
Apr-04-22 10:16AM
Mar-28-22 04:02PM
Mar-11-22 12:00PM
10:00AM
09:40AM
Mar-10-22 08:00AM
Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. Its products include bone graft harvest system, bone marrow aspirate kits, and soft tissue fixation system. The company was founded by Albert DaCosta, Frank Bono, Jim Riegler and Lee Rosenthal in 2010 and is headquartered in Englewood, CO.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DaCosta Albert See Remarks Mar 15 '24 Buy 9.12 28,000 255,226 5,339,110 Mar 18 05:34 PM DaCosta Albert see remarks Nov 10 '23 Buy 8.51 30,500 259,555 5,311,110 Nov 13 08:00 AM SCHNETTLER THOMAS P Director Jun 14 '23 Sale 18.54 6,900 127,952 29,129 Jun 16 05:24 PM WRIGHT KRISTINA Director Jun 06 '23 Sale 18.58 6,800 126,345 24,641 Jun 08 05:56 PM
Index RUT
P/E -
EPS (ttm) -1.47
Insider Own 55.63%
Shs Outstand 49.12M
Perf Week -32.12%
Market Cap 137.77M
Forward P/E -
EPS next Y -0.63
Insider Trans -0.14%
Shs Float 21.91M
Perf Month -29.90%
Income -68.00M
PEG -
EPS next Q -0.27
Inst Own 29.61%
Short Float 4.73%
Perf Quarter -49.27%
Sales 93.57M
P/S 1.47
EPS this Y 28.71%
Inst Trans 3.88%
Short Ratio 5.29
Perf Half Y -31.11%
Book/sh 0.66
P/B 4.21
EPS next Y 37.75%
ROA -44.01%
Short Interest 1.04M
Perf Year -51.90%
Cash/sh 1.25
P/C 2.24
EPS next 5Y -
ROE -181.72%
52W Range 2.78 - 8.80
Perf YTD -42.83%
Dividend Est. -
P/FCF -
EPS past 5Y -37.60%
ROI -59.37%
52W High -68.30%
Beta 1.42
Dividend TTM -
Quick Ratio 2.38
Sales past 5Y 23.82%
Gross Margin 49.47%
52W Low 0.36%
ATR (14) 0.34
Dividend Ex-Date -
Current Ratio 3.07
EPS Y/Y TTM 23.44%
Oper. Margin -59.70%
RSI (14) 24.57
Volatility 11.63% 6.36%
Employees 330
Debt/Eq 2.60
Sales Y/Y TTM 17.89%
Profit Margin -72.68%
Recom 1.38
Target Price 6.71
Option/Short Yes / Yes
LT Debt/Eq 2.50
EPS Q/Q 2.69%
Payout -
Rel Volume 3.46
Prev Close 2.90
Sales Surprise -24.63%
EPS Surprise -66.20%
Sales Q/Q -14.29%
Earnings May 13 AMC
Avg Volume 195.72K
Price 2.79
SMA20 -28.87%
SMA50 -35.89%
SMA200 -40.50%
Trades
Volume 677,251
Change -3.79%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-14-23 Initiated
Guggenheim
Neutral
Jul-05-23 Resumed
JP Morgan
Overweight
$18
Feb-02-23 Initiated
UBS
Buy
$14
Nov-03-22 Initiated
CapitalOne
Overweight
$19
Oct-06-22 Initiated
Stephens
Overweight
$16
Jun-22-22 Initiated
BTIG Research
Buy
$16
Jan-06-22 Resumed
Piper Sandler
Overweight
$23
May-11-21 Initiated
Piper Sandler
Overweight
$28
May-11-21 Initiated
Morgan Stanley
Overweight
$26
May-11-21 Initiated
JP Morgan
Overweight
$23
May-11-21 Initiated
Canaccord Genuity
Buy
$25
Show Previous Ratings
Today 08:02AM
May-14-24 01:55PM
09:01AM
08:14AM
07:34AM
08:54PM
Loading…
May-13-24 08:54PM
05:35PM
04:36PM
(Associated Press Finance)
04:00PM
May-09-24 08:00AM
May-06-24 10:00AM
08:00AM
May-02-24 08:00AM
Apr-22-24 04:05PM
Apr-05-24 08:00AM
09:52AM
Loading…
Mar-05-24 09:52AM
07:00AM
(Thomson Reuters StreetEvents)
Mar-04-24 08:51PM
05:31PM
05:15PM
04:21PM
(Associated Press Finance)
04:05PM
Feb-08-24 04:05PM
Feb-07-24 04:13AM
Jan-18-24 08:00AM
Jan-10-24 08:00AM
Jan-08-24 01:07AM
Jan-07-24 08:00AM
08:00AM
08:00AM
08:34AM
Loading…
Jan-05-24 08:34AM
Dec-27-23 09:55AM
Dec-20-23 08:05AM
Nov-12-23 10:51AM
Nov-09-23 10:25AM
(Thomson Reuters StreetEvents) +10.90%
Nov-08-23 05:51PM
04:05PM
(Associated Press Finance)
04:00PM
Nov-02-23 08:00AM
Nov-01-23 10:01AM
Oct-31-23 09:00AM
Oct-17-23 10:22AM
Oct-11-23 04:05PM
Sep-19-23 08:00AM
Aug-17-23 09:56AM
Aug-08-23 12:38PM
(Thomson Reuters StreetEvents)
Aug-07-23 06:15PM
05:02PM
(Associated Press Finance)
04:05PM
08:05AM
Aug-06-23 10:57AM
Jul-26-23 04:05PM
Jul-21-23 09:21AM
Jul-12-23 09:55AM
08:05AM
Jul-10-23 10:08AM
Jun-13-23 07:58PM
12:32PM
08:29AM
06:37AM
Jun-12-23 04:05PM
Jun-08-23 12:55AM
Jun-07-23 04:08PM
May-09-23 10:43AM
(Thomson Reuters StreetEvents)
May-08-23 05:35PM
04:32PM
04:05PM
May-05-23 07:36AM
Apr-27-23 08:00AM
Apr-17-23 12:20PM
Apr-14-23 03:38PM
Apr-12-23 08:00AM
08:00AM
Apr-06-23 08:00AM
Mar-20-23 04:00PM
Mar-09-23 05:17AM
Mar-08-23 07:21AM
Mar-07-23 09:52AM
(Thomson Reuters StreetEvents)
Mar-06-23 05:35PM
04:05PM
Feb-28-23 08:00AM
Feb-27-23 10:00AM
Feb-10-23 06:36PM
Feb-06-23 08:05AM
Feb-01-23 08:00AM
Jan-08-23 04:00PM
Jan-06-23 08:00AM
Dec-28-22 04:00PM
Dec-15-22 04:00PM
Dec-07-22 05:15AM
Nov-07-22 05:25PM
04:05PM
04:05PM
Nov-03-22 08:05AM
Oct-11-22 08:05AM
06:34AM
Oct-06-22 01:40PM
Aug-31-22 08:05AM
Aug-11-22 05:24PM
Aug-09-22 12:00AM
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. The company was founded by Garry Nolan, Yury Goltsev and Nikolay Samusik in 2015 and is headquartered in Marlborough, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
McKelligon Brian President and CEO Mar 20 '24 Option Exercise 0.30 7,500 2,272 239,368 Mar 22 05:54 PM McKelligon Brian President and CEO Mar 20 '24 Sale 4.97 7,500 37,243 231,868 Mar 22 05:54 PM McKelligon Brian President and CEO Mar 13 '24 Sale 4.94 7,500 37,035 224,368 Mar 14 08:41 PM McKelligon Brian President and CEO Dec 19 '23 Option Exercise 0.30 7,500 2,272 160,063 Dec 20 07:16 PM McKelligon Brian President and CEO Dec 19 '23 Sale 4.48 7,500 33,566 152,563 Dec 20 07:16 PM McKelligon Brian President and CEO Dec 12 '23 Option Exercise 0.30 7,500 2,272 160,063 Dec 14 04:24 PM McKelligon Brian President and CEO Dec 12 '23 Sale 4.25 7,500 31,871 152,563 Dec 14 04:24 PM McKelligon Brian President and CEO Nov 20 '23 Option Exercise 0.30 7,500 2,272 160,063 Nov 22 04:00 PM McKelligon Brian President and CEO Nov 20 '23 Sale 4.39 7,500 32,901 152,563 Nov 22 04:00 PM Pla Frederic Chief Operating Officer Sep 07 '23 Buy 4.60 20,000 92,014 20,000 Sep 11 04:00 PM Raffin Thomas A. Director Jun 12 '23 Buy 5.00 2,020,000 10,100,000 15,937,535 Jun 12 06:15 PM Winkler Matthew Director Jun 12 '23 Buy 5.00 203,388 1,016,940 984,513 Jun 12 06:16 PM SHEPLER ROBERT G Director Jun 12 '23 Buy 5.00 120,000 600,000 369,592 Jun 12 06:16 PM Ek John Frederick CFO Jun 12 '23 Buy 5.00 20,000 100,000 20,000 Jun 12 06:18 PM Mendel Scott Director Jun 12 '23 Buy 5.00 20,000 100,000 28,500 Jun 12 06:17 PM LAI GOLDMAN MYLA Director Jun 12 '23 Buy 5.00 20,000 100,000 20,000 Jun 12 06:18 PM McKelligon Brian President/CEO Jun 06 '23 Option Exercise 0.30 5,000 1,515 157,563 Jun 06 09:45 PM McKelligon Brian President/CEO Jun 06 '23 Sale 5.71 5,000 28,537 152,563 Jun 06 09:45 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite